What's New in Stomach Cancer Research?

Important research on stomach cancer is being done in many university hospitals, medical centers, and other institutions around the world. Scientists are learning more about what causes the disease and how best to treat it.

Risk factors


Research has clearly shown that differences in diet are an important factor in explaining variations in stomach cancer risk around the world.  Recent research in countries with relatively low stomach cancer risk has provided some insight into risk factors. Diets high in preserved meats and low in fresh fruits and vegetables have been linked with higher risk.

Helicobacter pylori infection

Recent studies have shown that certain types of H pylori (especially the cagA strains) are more strongly linked to stomach cancer.  Some inherited traits related to blood groups may also affect whether someone infected with H pylori will develop cancer. Further research is needed to help doctors determine how to use this information to test which people might be at higher risk for developing stomach cancer.

Recent research has also studied the interaction of H pylori infection with other risk factors. For example, they have found that a healthy diet is especially important for reducing stomach cancer risk for people infected with H pylori.


Chemoprevention is the use of natural or man-made chemicals to lower the risk of developing cancer. Some types of chemicals might be useful in helping prevent stomach cancer.


Many carcinogenic (cancer-causing) factors cause cells to form a type of chemical called a free radical. Free radicals can damage important parts of cells such as genes. Depending on how severe the damage is, the cells may die or they may become cancerous.

Antioxidants are a group of nutrients and other chemicals that can destroy free radicals or prevent them from forming. These nutrients include vitamin C, beta-carotene, vitamin E, and the mineral selenium. Studies that have looked at using dietary supplements to lower stomach cancer risk have had mixed results so far. There is some evidence that combinations of antioxidant supplements may reduce the risk of stomach cancer in people with poor nutrition to begin with. Further research in this area is needed.


Studies are being done to see whether antibiotic treatment of people who are chronically infected by H pylori will help prevent stomach cancer. Some studies have found that treating this infection may prevent pre-cancerous stomach abnormalities, but more research is needed.

Although not truly chemoprevention, antibiotics may help prevent stomach cancer from recurring in some cases. Research has shown that antibiotics may lower the risk that the cancer will come back in another part of the stomach in people who have been treated with endoscopic mucosal resection for early-stage stomach cancer.  Unfortunately, in the United States stomach cancers are more often found at a later stage, so it’s not clear how useful these results might be here.

Non-steroidal anti-inflammatory drugs (including aspirin)

Some (but not all) studies have found that people who take non-steroidal anti-inflammatory drugs (NSAIDs) such as aspirin or ibuprofen might have a lower risk of stomach cancer.  More research is needed to better define this possible link. In the meantime, doctors generally don’t recommend taking these medicines just to try to lower your risk of cancer, as they can cause serious side effects in some people.


Sentinel lymph node mapping

Doctors are trying to identify the spread of stomach cancer to lymph nodes using this technique,  which has proved very successful in melanoma and breast cancer.

In sentinel lymph node mapping, the surgeon injects a blue dye and/or a radioactive tracer substance into the cancer. These concentrate in the lymph nodes that would be the first site of cancer spread. Doctors can remove these lymph nodes and look for cancer. If no cancer is found in these lymph nodes, then the cancer is unlikely to have reached others, and a full lymph node removal might not be needed. If cancer is found in the sentinel lymph node(s), then all the lymph nodes would still need to be removed.

This technique has been shown to help find more lymph nodes to remove, and to find lymph nodes that are more likely to contain cancer cells. But this technique is still being studied in stomach cancer and is not yet ready for widespread use.


Chemotherapy drugs and combinations

Some studies are testing new ways to combine treatments already known to be active against stomach cancer or other cancers.

Several chemotherapy drugs are approved and used to treat stomach cancer, and some are used together in combination with each other.  Newer chemotherapy (chemo) drugs are also being studied. For example, S-1 is an oral chemo drug related to 5-FU.  This drug is commonly used for stomach cancer in some other parts of the world and continues to be studied, but it is not yet available in the United States. New ways of giving chemo are also being studied. For example, some doctors are looking at infusing chemo directly into the abdomen (intraperitoneal chemotherapy) to see if it might work better with fewer side effects.

Other studies are testing the best ways to combine chemo with radiation therapy, targeted therapies, or immunotherapy. A good deal of effort is being directed at improving the results of surgery by adding chemo and/or radiation therapy either before or after surgery. Some studies are also looking at benefits of giving chemo during surgery. Several clinical trials are in progress.

Targeted therapies

Chemo drugs target cells that divide rapidly, which is why they work against cancer cells. But there are other aspects of cancer cells that make them different from normal cells. In recent years, researchers have developed new targeted drugs to try to exploit these differences. Targeted drugs sometimes work when standard chemo drugs don’t. They also tend to have less severe side effects than chemo drugs.

Drugs that block HER2: Some stomach cancers have too much of the HER2 protein on the surface of their cells, which helps them grow. Drugs that target this protein might help treat these cancers. Trastuzumab (Herceptin) is already approved for use against advanced stomach cancer.  Other drugs that target HER2, such as lapatinib (Tykerb®), pertuzumab (Perjeta®), and trastuzumab emtansine (Kadcyla®) are now being studied in clinical trials.

Drugs that block EGFR: EGFR is another protein found on some stomach cancer cells that helps them grow. Panitumumab (Vectibix®) is a drug that targets EGFR that is being tested against stomach cancer. This drug is already FDA-approved to treat some other cancers.

Other targeted drugs: Other drugs target different parts of cancer cells. For example, another targeted drug being studied against stomach cancer is apatinib.

Most research in this area is looking at combining targeted agents with chemotherapy or with each other.


Immunotherapy is an approach that uses drugs to try and help the body’s immune system fight the cancer.

In 2017, pembrolizumab (Keytruda®) became the first immunotherapy agent approved to treat stomach cancer in some patients whose treatment did not work or stopped working. Pembrolizumab is an immune checkpoint inhibitor and targets PD-L1, a protein found on some stomach cancer cells.  For more information on this type of treatment, see Immunotherapy and Immune Checkpoint Inhibitors to Treat Cancer.

The American Cancer Society medical and editorial content team

Our team is made up of doctors and oncology certified nurses with deep knowledge of cancer care as well as journalists, editors, and translators with extensive experience in medical writing.

Balakrishnan M, George R, Sharma A, Graham DY. Changing trends in stomach cancer throughout the world. Curr Gastroenterol Reg. 2017;19:36.

Food and Drug Administration. FDA grants accelerated approval to pembrolizumab for advanced gastric cancer. 2017. Accessed at https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm577093.htm
on November 20, 2017.

Ford AC, Forman D, Hunt R, Yuan Y, Moayyedi P. Helicobacter pylori eradication for the prevention of gastric neoplasia. Cochrane Database of Systematic Reviews. 2015;7. Art. No.: CD005583.

Fukase K, Kato M, Kikuchi S, et al. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: An open-label, randomised controlled trial. Lancet. 2008;372:392–397.

Koizumi W, Akiya T, HaraT et al. S-1 plus cisplatin versus S-1 alone for first line treatment of advanced gastric cancer (SPIRITS trial): A phase III trial. Lancet Oncol. 2008;9:215–221.

LKS Biopharma. FDA grants apatinib orphan drug designation for treatment of gastric cancer. 2017. Accessed at http://lskbiopharma.com/the-us-fda-grants-apatinib-orphan-drug-designation-for-treatment-of-gastric-cancer/ on November 20, 2017.

National Cancer Institute. Physician Data Query (PDQ). Gastric Cancer Treatment. 2/2/2017. Accessed at: www.cancer.gov/cancertopics/pdq/treatment/gastric/HealthProfessional on November 20, 2017.

Shah M. Future directions in improving outcomes for patients with gastric and esophageal cancer. Hem Onc Clinics North America. 2017;31:545.

Shida A, Mitsumori N, Nimura H, Takano Y, Iwasaki T, Fujisaki M, Takahashi N, Yanaga K. Prediction of lymph node metastasis and sentinel node navigation surgery for patients with early-stage gastric cancer. World J Gastroenterol. 2016;22:7431-9.

Tian W, Zhao Y, Liu S, Li X. Meta-analysis on the relationship between nonsteroidal anti-inflammatory drug use and gastric cancer. Eur J Cancer Prev. 2010;19:288–298.

Wagner AD, Syn NLX, Moehler M, Grothe W, Yong WP, Tai BC, Ho J, Unverzagt S. Chemotherapy for advanced gastric cancer. Cochrane Database of Systematic Reviews. 2017;8. Art. No.: CD004064.

Walker R, Poleszczuk J, Mejia J, Lee JK, Pimiento JM, Malafa M, Giuliano AR, Enderling H, Coppola D. Toward early detection of Helicobacter pylori-associated gastric cancer. Gastric Cancer. 2017.

Last Medical Review: December 1, 2017 Last Revised: December 14, 2017

American Cancer Society medical information is copyrighted material. For reprint requests, please see our Content Usage Policy.